WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to... Read More

WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly... Read More

WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not... Read More

WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory... Read More

WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting (“PONV”) will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which... Read More

WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the... Read More

WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announced decision by the United States District Court for the District of Delaware finding that the 505(b)(2) drug... Read More

BARHEMSYS ® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis 1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the... Read More

WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the... Read More

CEO and Founder Scott Tarriff Retires Chairman Michael Graves to Serve as Interim Executive Chairman WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management. Effective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his... Read More

WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange... Read More

WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:... Read More

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book. 1 The ‘813 patent is directed to... Read More

J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis 1 and is also approved for the treatment... Read More

Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial Prize money to be donated to the University of Groningen Medical Center (“UMCG”) research fund, which supports the work of PhD students Eagle’s BYFAVO ® (remimazolam) for injection is approved for sedation in adults undergoing... Read More

WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023 as follows: Date: Wednesday, September 27, 2023 Time: 2.25PM ET Webcast: Click here To schedule a 1x1... Read More

CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease The first-in-human study showed positive safety and efficacy when added to standard of care in patients with severe community-acquired bacterial pneumonia WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc.... Read More

WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care (“SNACC”) Annual Meeting being held September 8-10, 2023, in Alexandria, VA. The conference is designed to meet the educational needs of neurosurgical and... Read More

Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for a more personalized treatment regimen in subpopulations, which represent over 50% of patients WOODCLIFF LAKE, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today... Read More

WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcare conferences: Citi's 2023 18 th Annual BioPharma Conference Date: Thursday, September 7, 2023 Time: 8:00AM ET Webcast: Click here H.C. Wainwright 25 th Annual... Read More

FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 Reflects strength of Eagle’s business and product pipeline; Company poised for sustained long-term growth WOODCLIFF LAKE, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today reiterated its previously issued guidance... Read More

Total revenue for Q2 2023 was $64.6 million Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share Q2 2023 net income was $5.2 million Q2 2023 adjusted non-GAAP EBITDA 1 was $20.7 million Gross margin was 74% for the first half of 2023, up from 73% for... Read More

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:... Read More

FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.70 1 FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 FY 2023 Adjusted non-GAAP R&D expense is reiterated at $41.0-$45.0 million 1 FY 2023 Adjusted non-GAAP SG&A expense is reiterated at $86.0-$90.0 million 1 WOODCLIFF LAKE, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the... Read More

Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century 1 CAL02 is a unique therapeutic agent that works differently from antibiotics, disarming an infectious pathogen’s virulence factors to reduce damage and mitigate disease CAL02 has been designed to neutralize a broad range of bacterial toxins to lessen the virulence effect on disease... Read More

WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance. “As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products. Through our well-trained and experienced sales force -- made up of 50 reps on... Read More

Company believes CAL02 is a new chemical entity (NCE), which would result in five years of marketing exclusivity upon approval or three years without NCE designation; total potential of eight or ten years of exclusivity Eagle has approved patents running until September 2035, with filed patent applications that would extend into 2037 or later Eagle may qualify for up to five additional years of patent term exclusivity, up to... Read More

WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, being held May 16-19, 2023, in Austin, Texas. “We are pleased to have the opportunity to present this investigative work at such a prestigious forum dedicated to... Read More

Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share Q1 2023 adjusted non-GAAP EBITDA of $22.3 million Q1 2023 net sales of PEMFEXY ® totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for... Read More

Byfavo 1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code for Byfavo® 1 (remimazolam for... Read More

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date... Read More

WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “Dr. Reddy’s”). Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug application referencing BENDEKA ® . Under the... Read More

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share 1 • FY 2022 revenue was $316.6 million... Read More

WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows: Date: Wednesday, March 15, 2023 Time: 2:35pm ET Webcast: Click Here To schedule a 1x1... Read More

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results... Read More

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from... Read More

WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference as follows: Date: Tuesday, January 10, 2023 Time: 10:30AM PT/1:30PM ET Webcast: Click Here The webcast of the presentation will be... Read More

Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)... Read More